Literature DB >> 12079155

Resectable gastric cancer: operative mortality and survival analysis.

Chia-Siu Wang1, Chin-Chuan Hsieh, Tzu-Chieh Chao, Yi-Yin Jan, Long-Bin Jeng, Tsann-Long Hwang, Min-Fu Chen, Pang-Chi Chen, Jen-Shi Chen, Swei Hsueh.   

Abstract

BACKGROUND: This study evaluated the survival outcome and determined the prognostic factors for gastric cancer patients who underwent gastric resection in the past 6 years.
METHODS: Between 1994 and 2000, a total of 1,322 patients with gastric cancer who underwent gastric resection in our hospital comprised the study subjects. Their mean age was 61.1 (range, 14-92) years. There were 865 male and 457 female patients. Total gastrectomy was performed in 389 (29.4%) and distal gastrectomy in 933 patients. Curative resection was performed in 961, and palliative resection in 361 patients. A D2 or greater lymphadenectomy was required for curative resection. Patients received postoperative chemotherapy if they underwent palliative resection.
RESULTS: Early or pT1 gastric cancer accounted for 17.7% and lymph node metastasis for 62.1% of all resected cases. The overall operative mortality and morbidity rates were 3.3% and 18.0%, respectively. The operative mortality for palliative total gastrectomy was particularly high (8.5%). The overall cumulative 5-year survival rate of all resected patients was 45.6%, and it was 57.0% after curative resection. Multivariate analysis revealed that lymph node metastasis, serosal invasion, peritoneal seeding, positive resection margin, liver metastasis, old age, tumor size, and lymphatic invasion were independent prognostic factors.
CONCLUSION: The most important prognostic factors for survival were lymph node metastasis, serosal invasion, peritoneal seeding, positive resection margin, liver metastasis, old age, tumor size, and lymphatic invasion. The operative mortality and survival outcome of our gastric cancer patients after gastric resection compared favorably with those of other series in other countries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079155

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  20 in total

Review 1.  A systematic review of surgery for non-curative gastric cancer.

Authors:  Alyson L Mahar; Natalie G Coburn; Simron Singh; Calvin Law; Lucy K Helyer
Journal:  Gastric Cancer       Date:  2011-10-28       Impact factor: 7.370

2.  Overexpression of ADP-ribosylation factor 1 in human gastric carcinoma and its clinicopathological significance.

Authors:  Ming-Ming Tsai; Paul Y Lin; Wan-Li Cheng; Chung-Ying Tsai; Hsiang-Cheng Chi; Cheng-Yi Chen; Yi-Hsin Tseng; Yi-Fen Cheng; Chi-De Chen; Ying Liang; Chia-Jung Liao; Sheng-Ming Wu; Yang-Hsiang Lin; I-Hsiao Chung; Chia-Siu Wang; Kwang-Huei Lin
Journal:  Cancer Sci       Date:  2012-03-28       Impact factor: 6.716

3.  [Advanced gastric cancer. Are there still indications for palliative surgical interventions?].

Authors:  I Gastinger; U Ebeling; L Meyer; F Meyer; U Schmidt; S Wolff; H Ptok; H Lippert
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

4.  MicroRNA-154 inhibits the growth and metastasis of gastric cancer cells by directly targeting MTDH.

Authors:  Wenhui Qiao; Nong Cao; Lei Yang
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

5.  High morbidity in myocardial infarction and heart failure patients after gastric cancer surgery.

Authors:  Sang-Ho Jeong; Young-Woo Kim; Wansik Yu; Sang Ho Lee; Young Kyu Park; Seong-Heum Park; In Ho Jeong; Sang Eok Lee; Yongwhi Park; Young-Joon Lee
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

6.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

Review 7.  [Surgical treatment of gastric carcinoma. German multicenter observational studies].

Authors:  K Ridwelski; I Gastinger; H Ptok; F Meyer; H Dralle; H Lippert
Journal:  Chirurg       Date:  2013-01       Impact factor: 0.955

8.  Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression.

Authors:  Shi Bin Yang; Fanghai Han; Jian Hai Wu; Zhi Zhao; Wenhua Zhan
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

9.  Clinical importance and surgical decision-making regarding proximal resection margin for gastric cancer.

Authors:  Doosup Shin; Sung-Soo Park
Journal:  World J Gastrointest Oncol       Date:  2013-01-15

10.  ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker.

Authors:  M- J Zhang; C- Z Zhang; W- J Du; X- Z Yang; Z- P Chen
Journal:  Clin Transl Oncol       Date:  2015-11-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.